WEST PHARMACEUTICAL SERVICES INC (WST) Financials
Annual revenue, profitability and per-share results for WEST PHARMACEUTICAL SERVICES INC, as reported in SEC filings.
Revenue • FY2025
$3.07B
▲ 6.3%YoY
Net income • FY2025
$493.7M
▲ 0.2%YoY
Gross margin • FY2025
35.9%
Diluted EPS • FY2025
$6.79
▲ 1.5%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $3.07B | $493.7M | $1.1B | $6.79 | $468.9M | 19.0% | +6.3% |
| FY2024 | $2.89B | $492.7M | $998.5M | $6.69 | $276.4M | 19.7% | -1.9% |
| FY2023 | $2.95B | $593.4M | $1.13B | $7.88 | $414.5M | 22.9% | +2.2% |
| FY2022 | $2.89B | $585.9M | $1.14B | $7.73 | $439.4M | 25.4% | +1.9% |
Figures as reported in WEST PHARMACEUTICAL SERVICES INC's 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a WST filing.
Get an email when WST files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.